Background and Aims: Macrophages, also termed phagocytes, are myeloid immune cells that are widely distributed throughout the tissues in the body. CD163, the hemoglobin-haptoglobin scavenger receptor, is lineage specific and expressed on the cell surface of macrophages and to some extent on monocytes. Upon macrophage activation, CD163 is shed and can be detected in the blood as soluble (s)CD163 and used as a circulating biomarker of macrophage activation. The important role of macrophages in inflammation and fibrosis in chronic liver diseases has increased the interest for systemic markers of macrophage activation. The aim is to study hepatic stiffness using ARFI, then to correlate the degree of stiffness with the level of soluble CD 163 in CHC patients.
Method: Liver fibrosis was assessed by Acoustic Radiation Force Impulse (ARFI) imaging,(Siemens ACUSON S2000 ultrasound system, Siemens Medical Solutions, Erlangen, Germany) and measured in m/s. sCD163 levels in patients with CHC, and HS were performed using commercially-available standard sandwich ELISA kit (SinoGeneClon Biotech, Hangzhou, China in 2007) according to the manufacturer's instruction.
Results: The study population included a total of 72 subjects of which 52 patients (CHC) infection and twenty healthy subjects (HS) were included as a control.
Conclusion:. This study suggest that sCD163 is promising noninvasive marker of macrophage activation in chronic hepatitis C patients